STERIS plc

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

A Look At STERIS (STE) Valuation After Recent Share Price Weakness

AI-generated analysis

πŸ“‰ STERIS (STE) shares have declined 14% over the past month and 15% over the past three months, contrasting with ongoing revenue and net income growth.

πŸ’° The stock currently trades at $214.57, representing a 1-day return of 1.05% and a 30-day recovery of 13.60% from recent lows.

πŸ“Š Long-term investors are noting a 4.87% total shareholder return over the past year despite short-term weakness.

βš–οΈ Simply Wall St analysis values STE at a fair price of $281.25, suggesting the stock is currently undervalued by approximately 23.6%.

πŸ’‘ The valuation model relies on steady growth assumptions and a low discount rate of 7.89%.

πŸ”¬ Continued expansion in consumables and services segments supports recurring revenue and margin visibility.

⚠️ Potential headwinds include tariff-related cost risks and ongoing healthcare reimbursement pressures that could impact margins.

πŸ“ˆ Current P/E ratio of 29.7x is slightly higher than the US Medical Equipment industry average of 28.1x and peer average of 27.2x.

🎯 Fair valuation models suggest the market multiple could stabilize around 30.1x over time.

πŸ’Ό The analysis highlights recurring revenue streams as a key driver behind the optimistic fair value forecast.

πŸ“‰ Investors are weighing whether the discount represents an attractive entry point or if expectations are already reflected in the price.

πŸ” Simply Wall St emphasizes that this analysis is based on historical data and forecasts, not financial advice.

🚫 The company has no position in STERIS and maintains an unbiased methodology for its valuations.

Bullish Signals
  • STERIS (STE) is currently trading at $214.57, which represents a significant discount to its fair value estimate of $281.25 according to analyst models.
  • The company demonstrates continued growth in both revenue and net income despite recent share price weakness, indicating potential for upside potential.
  • Expansion in consumables and services segments provides high recurring revenue and margin visibility, positioning STERIS to benefit from increasing healthcare expenditures.
  • Fair value calculations utilize steady growth assumptions and a relatively low discount rate of 7.89%, supporting a target upside based on valuation metrics.
  • The current P/E ratio of 29.7x is close to the model-suggested fair ratio of 30.1x, suggesting the market may move toward a premium multiple consistent with high quality fundamentals.
  • Recent trading activity shows positive momentum with a 1 day share price return of 1.05% and a 30 day return of 13.60%, offsetting longer-term weakness.
Risk Factors
  • The stock has underperformed significantly in the short term, down approximately 14% over the past month and 15% over the past 3 months.
  • Ongoing tariff-related cost risks and healthcare reimbursement pressures could weigh on profit margins despite revenue growth.
  • STERIS is currently trading at a P/E ratio of 29.7x, which exceeds the US Medical Equipment industry average of 28.1x and peer average of 27.2x.
  • The current stock price of $214.57 remains significantly below the fair value estimate of $281.25, suggesting valuation models rely on steady growth assumptions that may not hold if market conditions change.
  • Recent share price weakness contrasts with positive multi-year returns, creating potential confusion around future growth expectations.
Full Analysis
STERIS Inc (STE) has recently experienced a decline in share performance, with the stock dropping approximately 14% over the past month and 15% over the past three months. Despite this recent weakness, the company continues to report revenue and net income growth. As of the latest data, STE is trading at $214.57, which marks a 1-day return of 1.05%, a 30-day return of 13.60%, and a one-year total shareholder return of 4.87%. This recent pullback contrasts with a positive multi-year outcome and suggests the stock is currently trading below certain valuation estimates. Simply Wall St's analysis indicates that STERIS is valued at a discount to its estimated fair value, which stands at $281.25. This fair value is derived using steady growth assumptions and a relatively low discount rate of 7.89%. The positive valuation narrative is supported by the continued expansion of STERIS's consumables and services segments, which generate high recurring revenue and offer margin visibility. This positioning allows the company to benefit from increasing healthcare expenditures and the adoption of best practice infection control standards, supporting both revenue and margin expansion in the future. However, investors are advised to consider several pressure points that could impact the stock, including tariff-related cost risks and ongoing healthcare reimbursement pressures that may weigh on margins. While the current price-to-earnings ratio is 29.7x, this is slightly higher than both the US Medical Equipment industry average of 28.1x and the peer average of 27.2x. The model suggests the market could potentially move toward a fair P/E ratio of 30.1x, raising questions about whether investors are overpaying today or underestimating the duration of such premiums. The article notes that while the company appears undervalued based on fundamental analysis and recurring revenue growth, it remains important for investors to evaluate key risks before making decisions.